To investigate the long-term utility of adjuvant therapy after radical prostatectomy (RP) for prostate cancer with seminal vesicle invasion (SVI; pT3b), as the published data are conflicting.
Introduction
Although there has been a downward stage migration of prostate cancer [1, 2] about one-third of patients are still diagnosed with adverse pathological features such as seminal vesicles invasion (SVI), positive surgical margin (PSM) or node metastases (pN1) [3, 4] . A multimodal approach with extended pelvic lymph node dissection (PLND) [5] , adjuvant radiotherapy (aRT) [6] , and adjuvant hormonal therapy (aHT) [7] has been variably suggested for men with adverse preoperative characteristics or pathology at radical prostatectomy (RP). SVI, found in about 10% of RP specimens, is especially recognised as a poor prognostic indicator during RP [8, 9] . Yet the SVI literature remains relatively scarce and contradictory regarding the utility of adjuvant therapies in terms of long-term survivorship. For instance, series on SVI have largely been limited to 40-350 patients with median follow-ups in the 2-10 year range and have succeeded only in confirming the disease heterogeneity for pT3b prostate cancer [10] [11] [12] [13] . Some of these investigations have supported aRT [10] , while another supported aHT + aRT [13] , and yet others supported forgoing aRT all together [14] . When members of our own group have examined the topic of SVI [15, 16] , they found aHT to be associated with improved metastasis and cancer-specific survival but not overall survival.
To reconcile the inconsistencies on adjuvant therapies in the SVI literature, we queried the experience of two tertiary care referral institutions to create the largest series of patients with prostate cancer and SVI treated with RP (3 279 patients) with a median follow-up of >10 years. A pre-planned subset analysis of adjuvant therapy in pT3bN0 and pT3bN+ patients was also undertaken.
Patients and Methods
We evaluated data on 3 279 consecutive patients with prostate cancer and SVI treated with RP and PLND between January 1986 and December 2014 at two major referral centres. Only patients who harboured SVI at RP were included in the study. We excluded every patient with pTx (112 patients), history of neoadjuvant treatments (378), and without authorisation to use their records/incomplete followup (193) . Both Institutional Review Boards approved the study. Patients were staged preoperatively with pelvic/ abdominal CT or abdominal ultrasonography, bone scan and chest X-ray. Nerve-sparing techniques were offered when oncologically safe according to preoperative patient characteristics and the clinical judgment of the treating physicians. Adjuvant treatments were defined as treatments initiated within 90 days of RP. Adjuvant therapy indications were based on the clinical judgment of each treating physician, according to patient and tumour characteristics.
Adjuvant treatments consisted of aRT and aHT. aRT was given using the previously described technique [17] . aHT therapy consisted of either orchidectomy, combined androgen blockade or LHRH agonist alone. aHT was intended to be lifelong, but given the retrospective nature of the cohort, we do not have data on which patients discontinued treatment. Biochemical recurrence (BCR) was defined as a serum PSA level of ≥0.2 ng/mL after RP for two consecutive measurements. Vital status and cause of death were identified from death certificates and physician correspondence. On death certificates, prostate cancer was considered the cause of death when it was mentioned as the first cause on the list.
Standard descriptive statistics, chi-squared and MannWhitney tests were used where applicable. Kaplan-Meier analyses were used to evaluate BCR, cancer-specific mortality (CSM) and overall mortality (OM) free rates. Second, multivariable Cox regression analyses were used to predict metastases, CSM and OM. Covariates in multivariate models included age at RP, year of surgery, number of positive nodes, PSM, aRT administration, aHT administration, and treatment institution. These analyses were repeated for the subset of pT3bN0 and pT3bN+ patients. Statistical analyses were performed using the R statistical package (R Foundation for Statistical Computing, Vienna, Austria) and Statistical Package for the Social Sciences (SPSS) version 20.0 (IBM Corp., Armonk, NY, USA), considering statistical significance at P < 0.05.
Results

Baseline Patient Characteristics
Clinical and pathological demographics of the cohort stratified according pathological N stage are reported in 
Survival Estimates and Cox Regression Analyses for the Overall Cohort
The mean and median follow-up periods were 142 and 148 months, respectively. Survival curves for BCR, CSM and OM are shown in Fig. 1 for all SVI patients. The 1-, 3-, 5-and 10-year event-free survival rates were: i) 78%, 60%, 50%, and 36% for BCR-free survival; ii) 99%, 98%, 94%, and 86% for cancer-specific survival; and iii) 99%, 95%, 90%, and 73% for overall survival, respectively ( Fig. 1A-C ).
Multivariable Cox regression analyses (Table 2) found that aRT was a significant multivariable predictor of BCR [hazard ratio (HR) 0.83, P = 0.02] and CSM (HR 0.69, P = 0.02) and OM (HR 0.85, P = 0.03). Similarly, aHT was associated with improved BCR (HR 0.46, P < 0.001), CSM (HR 0.71, P = 0.01), and OM (HR 0.79, P = 0.004). Interestingly, PSMs were strongly associated with increased risk of BCR (HR 1.32, P < 0.001), CSM (HR 1.37, P = 0.007) and OM (HR 1.20, P = 0.01).
Subset Analysis of SVI and pN0 vs SVI and pN+
The subset of 2 038 pT3bN0 patients was analysed to determine if these observations applied to patients without lymph node invasion. Of these patients, 1 195 (58.6%) received no adjuvant therapy, 565 (27.7%) received aHT, 133 (6.5%) received aRT, and 145 (7.1%) received both aHT and aRT. On multivariable Cox regression (Table 3) , aHT was associated with improved BCR-free survival (HR 0.50,
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© 2016 The Authors BJU International © 2016 BJU International P < 0.001), cancer-specific survival (HR 0.62, P = 0.01), and OM (HR 0.75, P = 0.004). aRT was not associated with improvement in these outcomes on multivariable analysis (all P > 0.05). Table 4 shows the subset analyses of the 1 241 patients with pT3bN+ disease. Of these, 192 (15.5%) received no adjuvant therapy, 614 (49.5%) received aHT, 328 (26.4%) received aRT, and 107 (8.6%) received both aHT and aRT. On multivariable Cox regression, aRT was associated with improved BCR-free survival (HR 0.76, P = 0.04), cancerspecific survival (HR 0.64, P = 0.03), and OM (HR 0.73, P = 0.04). Conversely, the use of aHT was associated with an increase in BCR-free rates (HR 0.83, P = 0.04), but no effect on CSM (HR 0.65, P = 0.03) and OM (HR 0.78, P = 0.03).
When multivariable analyses were performed, analysing aRT and aHT together, there was no impact on CSM (P > 0.1).
Discussion
As prior series on SVI have been underpowered and offer conflicting recommendations on adjuvant therapy [8, 10, 11, 13, 14] , in the present study we analysed the largest series of RP with SVI (3 279 patients) with the longest follow-up (median follow-up 148 months) to explore the utility of adjuvant therapies. We found that aRT was associated with improved survival with improvement in BCR (HR 0.83, P = 0.02), CSM (HR 0.69, P = 0.02) and OM (HR 0.85, P = 0.03) rates. However, aRT was not a significant determinant of BCR, CSM or OM when node-positive patients were excluded. aHT, on the other hand, was associated with improved BCR, CSM and OM. Finally, when only pT3bN+ patients were considered, aRT was a predictor of improved BCR, CSM, and OM. This effect was not evident considering aHT. Our present study thus reconciles the literature and supports aRT + aHT for pT3b patients, aHT alone for pT3bN0 patients and aRT alone for pT3bN+ patients.
The concept of aRT after RP has been examined by randomised clinical trials, and these largely support our present finding that aRT is not associated with improved metastasis or survival outcomes in pT3bN0 men. The 10-year follow-up data from the ARO 96-02/AUO AP 09/95 trial [18] revealed that aRT decreased rates of BCR among pN0 men with SVI but did not improve metastasis or cancerspecific survival. These findings were echoed by the 10-year follow-up data of European Organisation for the Research and Treatment of Cancer (EORTC) 22 911 [19] , which contained a cohort of 256 pT3bN0 men and found that aRT improved BCR but not metastasis or survival. However, the primary endpoint of both these trials was BCR and might have been underpowered to evaluate other more important survival outcomes. In fact, Southwest Oncology Group (SWOG) S8794 [20] was the only randomised trial to show an improvement in metastasis and survival at 10 years. Thus, our present finding that aRT is not associated with improved metastasis or survival in the pT3bN0 population in fact agrees with two of the three randomised trials on the subject and other retrospective series [9, 21] .
On the other hand, we found aHT was associated with improved BCR-free, CSM, and overall survival for the subset of pT3bN0 men and this finding is particularly relevant in the absence of randomised clinical trial data for SVI after RP. In fact the only two trials of aHT for locally advanced prostate cancer after RP tested adjuvant bicalutamide or flutamide monotherapy vs observation and unsurprisingly, considering the inadequacy of the androgen blockade, did not find a benefit [22, 23] . The present investigation extends prior reports from our group [15, 16] that were only able to show a trend towards improved overall survival for aHT in pT3bN0 patients (i.e. 0.05 < P value < 0.10). Now with extended follow-up and increased power, we have found this association does become statistically significant. Thus, our present study underscores the need for a randomised clinical trial on aHT (with GnRH modulators or orchidectomy) in men found to have SVI at RP.
Furthermore, our present study also found a benefit to aRT when node-positive SVI patients were included in the analysis. This finding is consistent with several reports [14, 24, 25] from our group describing the benefit of aRT after RP for node-positive patients with concurrent high-risk features, such as SVI in this case. Unfortunately, the three aforementioned randomised trials of aRT [18] [19] [20] [7] .
Patients with SVI are a heterogeneous population and several factors may influence oncological outcomes. We found an impact of both aHT and aRT on improving survival after RP. However, after stratifying according to node status, we found that patients without nodal metastases benefited from aHT only and patients with nodal metastases benefited from aRT.
From an oncological perspective, this can be due to the increased risk of local-regional recurrence even in nodepositive disease [28] . Further, the impact of aRT on this subset of patients was previously described in a report from our centres [24] . On the other hand, it is not clear why aHT falls out of the model and further investigations are warranted. Certainly, it is possible that these pN0 patients may have harboured occult disease and thus benefited from systemic treatment.
Lastly, our present analysis confirmed the importance of local margin control for patients with SVI by finding that PSMs were associated with increased risk of BCR (HR 1.32, P < 0.001), CSM (HR 1.37, P = 0.007), and OM (HR 1.20, P = 0.01). Other investigators have debated the importance of margin status in SVI: with most series finding a significant impact [8, 10, 21] , while another recent report found no significant association [14] . A recent review highlights the conflicting evidence about the impact of PSMs on concrete endpoints such as metastasis and survival [29] . Our group has shown that PSMs remain an independent predictor of survival for locally advanced patients [30] and even for pN1 patients [25, 31] . Our hypothesis is that PSMs are likely reflective of several factors, such as tumour volume, tumour shape, tumour differentiation, and quality of surgical resection, which coalesce to create a PSM. When the tumour left behind is of a higher grade, then this margin is more likely to translate to adverse clinical outcomes [32] .
Our present study is subject to the commonly cited limitations of retrospective observational data. For example, treatment within 90 days after RP has been categorised as adjuvant but some of these patients may have been submitted to a salvage treatment in relation to PSA persistence after RP. However, it is important to note that upcoming randomised trials [26, 27] will not address the utility of aRT in pT3bN1 patients, and there are no major randomised trials proposed to evaluate aHT in pT3bN0 patients. Thus, in the absence of such reports, our present study represents an important step in guiding adjuvant treatment for patients with SVI. Second, a central pathological re-review was not performed in our present cohort. Nonetheless, dedicated genitourinary pathologists in each institution usually examined the pathological specimens. Third, no data about differences in pattern of SVI or PSM were recorded or analysed, and our study also did not account for the role of genomic classifiers in guiding adjuvant treatment. Fourth, our present study includes patients treated in a prolonged study period. Therefore, differences in patients and tumour (such as Gleason score modifications) characteristics have occurred over the years. To partially address these limitations, the year of surgery was included in our multivariable models. Fifth, data about comorbidity were not universally available for this surgical cohort and may factor in assessment of OM.
Conclusions
In the largest series of patients with SVI with the longest follow-up available to date, we found that aRT and aHT were associated with improved survival in pT3b patients. However, when separate sub-analyses were performed in N+ vs N0 subgroups, aHT was effective only in pT3bN0 patients. On the other hand, aRT remained significant only when considering pT3bN+ patients. In the absence of randomised trials evaluating these questions, our present results may serve to guide adjuvant therapy for men found to have SVI at RP.
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